AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16293966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus-preserving Kausch-Whipple (PP-KW)
Number of subjects: 550
Study 16293966 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Kausch-Whipple (KW)
Number of subjects: 550
Study 16293966 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative complications
Number of subjects: 550
Study 16293966 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 550
Study 12095484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical insemination samples
Number of subjects: 75
Study 12095484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination samples
Number of subjects: 75
Study 10673878 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 0.1 mg kg‐1 to a maximum of 5 mg
Number of subjects: 58
Study 10673878 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 58
Study 8766474 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoperfusion balloon PTCA
Number of subjects: 158
Study 8766474 — intervention group
Group type: COMPARATOR
Intervention: Conventional PTCA
Number of subjects: 158
Study 1918581 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 or 120 mg)
Number of subjects: 23
Study 1918581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7249345 — intervention group
Group type: EXPERIMENTAL
Intervention: one puff in each nostril four times daily
Number of subjects: 123
Study 7249345 — intervention group
Group type: EXPERIMENTAL
Intervention: two puffs in each nostril twice daily
Number of subjects: 123
Study 7249345 — intervention group
Group type: EXPERIMENTAL
Intervention: four puffs in each nostril once per day
Number of subjects: 123
Study 30465137 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent calcium magnesium citrate (EffCaMgCit)
Number of subjects: 18
Study 30465137 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate (CaAc)
Number of subjects: 18
Study 29093152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (POM)
Number of subjects: 23
Study 29093152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 23
Study 27544837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 45
Study 27544837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25019571 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib 800 mg orally every day until disease progression or prohibitive toxicity
Number of subjects: 45
Study 22110164 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% solution
Number of subjects: 28
Study 22110164 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.1% hydrogel
Number of subjects: 28
Study 22110164 — intervention group
Group type: EXPERIMENTAL
Intervention: Both timolol formulations
Number of subjects: 28
Study 20346136 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus mobile phone reminders (automated call and picture message, delivered once a week)
Number of subjects: 600
Study 20346136 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 600
Study 17537764 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg daily azithromycin
Number of subjects: 208
Study 17537764 — intervention group
Group type: COMPARATOR
Intervention: 1,200 mg weekly azithromycin
Number of subjects: 208
Study 17537764 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg daily azithromycin (in patients aged <18 yrs)
Number of subjects: 208
Study 17537764 — intervention group
Group type: COMPARATOR
Intervention: 1,200 mg weekly azithromycin (in children)
Number of subjects: 208
Study 16214597 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 90056
Study 11684377 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CA) 10 mg/day
Number of subjects: 336
Study 11684377 — intervention group
Group type: COMPARATOR
Intervention: Micronized progesterone (P) 200 mg/day
Number of subjects: 336
Study 9455602 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign Focal Epilepsy of Childhood with Occipital Paroxysms (BEOP)
Number of subjects: 11
Study 9455602 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic occipital lobe epilepsy
Number of subjects: 11
Study 8187108 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nitroglycerin (NTG) - acute administration (2 days)
Number of subjects: 10
Study 8187108 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) - continuous administration (24 days)
Number of subjects: 10
Study 8187108 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) - intermittent administration (24 days)
Number of subjects: 10
Study 3370064 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 6
Study 3370064 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 6
Study 31373899 — intervention group
Group type: EXPERIMENTAL
Intervention: New reference values for sonographic estimated fetal weight (sEFW) in twin gestations
Number of subjects: 195
Study 31373899 — intervention group
Group type: COMPARATOR
Intervention: Comparison to previously published sEFW normograms for twin gestations
Number of subjects: 195
Study 27736248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (NIT) - 70 mL of beetroot juice containing 4 mmol NO3‐ for 8 days
Number of subjects: 8
Study 27736248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) - NO3‐-depleted placebo for 8 days
Number of subjects: 8
Study 25028991 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training followed by strength (ES)
Number of subjects: 14
Study 25028991 — intervention group
Group type: COMPARATOR
Intervention: Strength training followed by endurance (SE)
Number of subjects: 14
Study 24150466 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief patient-centered HIV risk-reduction counseling with a rapid HIV test
Number of subjects: 5012
Study 24150466 — intervention group
Group type: COMPARATOR
Intervention: Rapid HIV test with information only (control group)
Number of subjects: 5012
Study 21765964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass treatment with anti-filarial drugs (4 annual administrations)
Number of subjects: 16480
Study 21765964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass treatment with anti-filarial drugs in communities with high pre-treatment transmission (224-742 infective bites/person/year)
Number of subjects: 16480
Study 21765964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass treatment with anti-filarial drugs in communities with moderate pre-treatment transmission (24-167 infective bites/person/year)
Number of subjects: 16480
Study 19478342 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplement provided in the morning and evening (n = 13)
Number of subjects: 33
Study 19478342 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplement provided immediately before and immediately after workouts (n = 13)
Number of subjects: 33
Study 19478342 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7) with no protein or other nutritional supplement
Number of subjects: 33
Study 17373187 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic agents
Number of subjects: 0
Study 15196600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation of nortriptyline
Number of subjects: 92
Study 11282251 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg/day
Number of subjects: 27
Study 11282251 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 27
Study 11282251 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 100 mg/day
Number of subjects: 27
Study 11282251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9198080 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid non‐caloric meal (5 mL water kg‐1)
Number of subjects: 30
Study 9198080 — intervention group
Group type: EXPERIMENTAL
Intervention: Second meal given within one hour after the first meal
Number of subjects: 30
Study 9198080 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic 3 cycles per minute (CPM) signal observed after a meal
Number of subjects: 30
Study 9198080 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic 3 CPM signal during fasting state
Number of subjects: 30
Study 9198080 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of gastric emptying pattern with epigastric impedance
Number of subjects: 30
Study 9198080 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigastric impedance measurement
Number of subjects: 30
Study 8471370 — intervention group
Group type: EXPERIMENTAL
Intervention: re‐IVRA
Number of subjects: 120
Study 8471370 — intervention group
Group type: COMPARATOR
Intervention: IVRA
Number of subjects: 120
Study 4042306 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone (10 mg iv followed by a continuous infusion of 10 mg/hr)
Number of subjects: 12
Study 4042306 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 12
Study 28939661 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe sleep health education intervention delivered as part of the 2-week WCV
Number of subjects: 0
Study 28939661 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control group receiving a scald burn prevention intervention
Number of subjects: 0
Study 28939661 — intervention group
Group type: COMPARATOR
Intervention: Standard of care group
Number of subjects: 0
Study 29932345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide
Number of subjects: 244
Study 27265121 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic Paravertebral Block (TPVB)
Number of subjects: 100
Study 27265121 — intervention group
Group type: COMPARATOR
Intervention: Epidural Anesthesia (EA)
Number of subjects: 100
Study 25636293 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride vanish, semi‐annual application
Number of subjects: 1016
Study 25636293 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin sealant, single placement
Number of subjects: 1016
Study 25636293 — intervention group
Group type: COMPARATOR
Intervention: Fluoride foam, semi‐annual application
Number of subjects: 1016
Study 25636293 — intervention group
Group type: COMPARATOR
Intervention: Placebo control with oral hygiene instruction
Number of subjects: 1016
Study 22290354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saver group
Number of subjects: 170
Study 22290354 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170
Study 20095977 — intervention group
Group type: EXPERIMENTAL
Intervention: Triathletes
Number of subjects: 78
Study 20095977 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 78
Study 18528294 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tumor lysate-pulsed dendritic cell (DC) vaccine administered every other week for 3 doses
Number of subjects: 24
Study 18528294 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tumor lysate-pulsed DC vaccine followed by low-dose IL-2
Number of subjects: 24
Study 18528294 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tumor lysate-pulsed DC vaccine followed by high-dose IL-2
Number of subjects: 24
Study 18528294 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 24
Study 15912460 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL-Master (Zeiss)
Number of subjects: 34
Study 15912460 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratometer (Zeiss)
Number of subjects: 34
Study 15912460 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal topograph (EyeSys Technologies)
Number of subjects: 34
Study 15912460 — intervention group
Group type: COMPARATOR
Intervention: Clinical history method (chm)
Number of subjects: 34
Study 14629807 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care urine test for smoking with visual and numerical feedback
Number of subjects: 856
Study 14629807 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care urine test for smoking
Number of subjects: 856
Study 14629807 — intervention group
Group type: COMPARATOR
Intervention: Control group received anti-smoking counselling as part of routine care
Number of subjects: 856
Study 14629807 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined smoking test results at 36 weeks
Number of subjects: 856
Study 10690134 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg kg‐1
Number of subjects: 70
Study 10690134 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg kg‐1
Number of subjects: 70
Study 10690134 — intervention group
Group type: COMPARATOR
Intervention: Rapacuronium 1.5 mg kg‐1 with three incremental doses of 0.5 mg kg‐1
Number of subjects: 70
Study 10690134 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine vs Edrophonium after three incremental doses of rapacuronium
Number of subjects: 70
Study 8701899 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-18790
Number of subjects: 21
Study 8701899 — intervention group
Group type: COMPARATOR
Intervention: dobutamine
Number of subjects: 21
Study 8445303 — intervention group
Group type: EXPERIMENTAL
Intervention: Head dressing
Number of subjects: 100
Study 8445303 — intervention group
Group type: COMPARATOR
Intervention: No head dressing
Number of subjects: 100
Study 3080114 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine derived from yeast
Number of subjects: 50
Study 3080114 — intervention group
Group type: COMPARATOR
Intervention: Plasma derived hepatitis B vaccine
Number of subjects: 50
Study 30359369 — intervention group
Group type: EXPERIMENTAL
Intervention: Social stress
Number of subjects: 100
Study 30359369 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical stress
Number of subjects: 100
Study 30359369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of social and physical stress
Number of subjects: 100
Study 30359369 — intervention group
Group type: EXPERIMENTAL
Intervention: Social anxiety
Number of subjects: 100
Study 26732694 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 100
Study 26732694 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope
Number of subjects: 100
Study 23374977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate care for 48 hours
Number of subjects: 400
Study 23374977 — intervention group
Group type: COMPARATOR
Intervention: Surgical ward care
Number of subjects: 400
Study 20656725 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session counselling
Number of subjects: 1339
Study 20656725 — intervention group
Group type: COMPARATOR
Intervention: Non-counselling
Number of subjects: 1339
Study 19761115 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoon-needle cluster (SNO) treatment
Number of subjects: 164
Study 19761115 — intervention group
Group type: COMPARATOR
Intervention: Filiform-needle cluster (FNC) treatment
Number of subjects: 164
Study 17174593 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure (0.15 ppm to 1.0 ppm)
Number of subjects: 21
Study 17174593 — intervention group
Group type: COMPARATOR
Intervention: Control 1 (buccal smears prepared 1 week before the study)
Number of subjects: 21
Study 17174593 — intervention group
Group type: COMPARATOR
Intervention: Control 2 (buccal smears at the start of the study before first exposure)
Number of subjects: 21
Study 15328078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran (E5564) 500 microg/h
Number of subjects: 0
Study 15328078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran (E5564) 2,000 microg/h
Number of subjects: 0
Study 15328078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran (E5564) 3,500 microg/h
Number of subjects: 0
Study 15328078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran (E5564) 500 to 3,500 microg/h
Number of subjects: 0
Study 15328078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran (E5564)
Number of subjects: 0
Study 12241627 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate (CB) 0.05% cream
Number of subjects: 18
Study 12241627 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC) 1% cream
Number of subjects: 18
Study 12241627 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study 9273824 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 1594
Study 9273824 — intervention group
Group type: COMPARATOR
Intervention: Control (other antihypertensive agents)
Number of subjects: 1594
Study 8508282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 3578745 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium and sodium chloride (group A)
Number of subjects: 75
Study 3578745 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium aspartate (group B)
Number of subjects: 75
Study 3578745 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced solution of electrolytes and trace metals (Inzolen) with aspartate as the anion (group C)
Number of subjects: 75
Study 3578745 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace metals supplementation (group C)
Number of subjects: 75
Study 28118307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Power Training (HIPT)
Number of subjects: 29
Study 28118307 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Power Training (TPT)
Number of subjects: 29
Study 28118307 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 29
Study 27159758 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral suspension
Number of subjects: 374
Study 27159758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous suspension
Number of subjects: 374
Study 27159758 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 374
Study 24477778 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks or 420 mg every month
Number of subjects: 300
Study 24477778 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (control)
Number of subjects: 300
Study 24477778 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 300
Study 23192752 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral self-help intervention
Number of subjects: 196
Study 23192752 — intervention group
Group type: COMPARATOR
Intervention: Control group (online psychoeducative information modules)
Number of subjects: 196
Study 23192752 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 196
Study 21197850 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% O2:21% N2:4% Ar
Number of subjects: 10
Study 21197850 — intervention group
Group type: EXPERIMENTAL
Intervention: 56% O2:42% N2:2% Ar
Number of subjects: 10
Study 21197850 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 10
Study 18427501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (coaxil) - serotonin reuptake enhancer
Number of subjects: 43
Study 18427501 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (zofort) - selective serotonin reuptake inhibitor
Number of subjects: 43
Study 18427501 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 43
Study 16161725 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher-based contingency management for substance abuse treatment (criminal justice involved)
Number of subjects: 0
Study 16161725 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher-based contingency management for substance abuse treatment (non-criminal justice involved)
Number of subjects: 0
Study 16161725 — intervention group
Group type: COMPARATOR
Intervention: Voucher-based contingency management (both groups)
Number of subjects: 0
Study 14525573 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent blue dye (PB)
Number of subjects: 104
Study 14525573 — intervention group
Group type: COMPARATOR
Intervention: Triple modality (TM)
Number of subjects: 104
Study 11252342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 6 g/day by continuous infusion
Number of subjects: 18
Study 11252342 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime bolus dosing (2 g 8 hourly)
Number of subjects: 18
Study 8696250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-test cigarette
Number of subjects: 20
Study 8696250 — intervention group
Group type: COMPARATOR
Intervention: No pre-test cigarette
Number of subjects: 20
Study 1835276 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (a nonspecific inhibitor of thromboxane synthesis)
Number of subjects: 0
Study 1835276 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulotroban (a specific thromboxane receptor antagonist)
Number of subjects: 0
Study 1835276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6820183 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic diet
Number of subjects: 10
Study 6820183 — intervention group
Group type: COMPARATOR
Intervention: Average Danish food
Number of subjects: 10
Study 31939063 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐SZ‐IFX (biosimilar group)
Number of subjects: 650
Study 31939063 — intervention group
Group type: EXPERIMENTAL
Intervention: IFX‐EU (week 30 switch group)
Number of subjects: 650
Study 31939063 — intervention group
Group type: EXPERIMENTAL
Intervention: IFX‐EU (week 54 switch group)
Number of subjects: 650
Study 31939063 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐SZ‐IFX
Number of subjects: 650
Study 31521942 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational Cognitive Ability Training by the Japanese Cognitive Rehabilitation Program for Schizophrenia (VCAT‐J)
Number of subjects: 31
Study 31521942 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus VCAT‐J
Number of subjects: 31
Study 31521942 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (TAU)
Number of subjects: 31
Study 28726512 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total HMO concentration
Number of subjects: 11
Study 28726512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialylated HMOs
Number of subjects: 11
Study 28726512 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fucosylated/non-sialylated HMOs
Number of subjects: 11